Notice of Proposed Sale · 144
Tarsus Pharmaceuticals, Inc.
TARSNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Tarsus Pharmaceuticals, Inc.
- Issuer CIK
- 0001819790
- SEC file number
- 001-39614
- Phone
- (949) 409-9820
- Person for whose account securities are to be sold
- Mottiwala Aziz
- Relationships to issuer
- Former Officer
- Street
- 15440 LAGUNA CANYON ROAD
- City
- IRVINE
- State / country code
- CA
- Postal code
- 92618
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 81,332 | 5,843,886.98 | 43,882,996 | 08/25/2026 | NASDAQ | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/25/2026 | Stock Option Exercise | Issuer | 81,332 | N | 08/25/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Aziz A. Mottiwala | Common | 08/19/2026 | 53,043 | 3,842,690.85 |
Seller — prior-sale row 1, entry 1
- Name
- Aziz A. Mottiwala
- Street
- 17700 Laguna Canyon Road
- Street (continued)
- Floor 4
- City
- Irvine
- State / country code
- CA
- Postal code
- 92618
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/25/2026
- Signed
- /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Aziz Mottiwala
Company context
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.